Safety and tolerability of regadenoson CMR

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 7, 2014, Pages 753-760

  Nguyen, Kim Lien ^a,b   Bandettini, W Patricia ^a   Shanbhag, Sujata ^a   Leung, Steve W ^a,c   Wilson, Joel R ^a,d   Arai, Andrew E ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular MRI; Coronary artery disease; Myocardial perfusion; Perfusion imaging; Regadenoson; Vasodilator agents

Indexed keywords

AMINOPHYLLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GADOLINIUM PENTETATE MEGLUMINE; GLYCERYL TRINITRATE; METOPROLOL; REGADENOSON; VASODILATOR AGENT; CONTRAST MEDIUM; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; BODY MASS; BRONCHOSPASM; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST MEDIUM EXTRAVASATION; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECTOPIA CORDIS; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART PERFUSION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY; SCINTIGRAPHY; THORAX PAIN; THROMBOPHLEBITIS; URTICARIA; VERY ELDERLY; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; DRUG TOLERANCE; EVALUATION STUDY; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; NONPARAMETRIC TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; STATISTICAL MODEL; YOUNG ADULT;

ADULT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DRUG TOLERANCE; FEMALE; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PATIENT SAFETY; PURINES; PYRAZOLES; RISK ASSESSMENT; ROC CURVE; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84898414029     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jet278     Document Type: Article

References (36)

1. Zoghbi GJ, Iskandrian AE. Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol 2012;19:126-41.
2. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75. (Pubitemid 41713594)
3. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58. (Pubitemid 47355078)
4. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16. (Pubitemid 351676842)
5. Palani G,Husain Z, SalinasRC, KarthikeyanV, KarthikeyanAS, AnanthasubramaniamK. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol 2011; 18:605-11.
6. Ananthasubramaniam K,Weiss R, McNutt B, Klauke B, Feaheny K, Bukofzer S.Arandomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease. J Nucl Cardiol 2012;19: 319-29.
7. AljaroudiW, Iqbal F, Koneru J, Bhambhvani P, Heo J, Iskandrian AE. Safety of regadenoson in patients with end-stage liver disease. J Nucl Cardiol 2011;18:90-5.
8. Cavalcante JL, Barboza J, Ananthasubramaniam K. Regadenoson is a safe and welltolerated pharmacological stress agent for myocardial perfusion imaging in postheart transplant patients. J Nucl Cardiol 2011;18:628-33.
9. Husain Z, Palani G, Cabrera R, Karthikeyan AS, Dhanalakota S, Pathmanathan S et al. Hemodynamic response, arrhythmic risk, and overall safety of Regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients. Int J Cardiovasc Imaging 2012;28: 1841-9.
10. Prenner BM, Bukofzer S, Behm S, Feaheny K, McNutt BE. A randomized, doubleblind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92.
11. Tarroni G, Corsi C, Antkowiak PF, Veronesi F, Kramer CM, Epstein FH et al. Myocardial perfusion: near-automated evaluation from contrast-enhanced mr images obtained at rest and during vasodilator stress. Radiology 2012;265:576-83.
12. Dibella EV, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B et al. The effect of obesityon regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study. Int J Cardiovasc Imaging 2012;28:1435-44.
13. Jekic M, Ding Y, Dzwonczyk R, Burns P, Raman SV, Simonetti OP. Magnetic field threshold for accurate electrocardiography in the MRI environment. Magn Reson Med 2010;64:1586-91.
14. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B,WangW et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 2009;157:771-6.
15. Bernhardt P, Levenson B, Engels T, Strohm O. Contrast-enhanced adenosine-stress magnetic resonance imaging-feasibility and practicability of a protocol for detection or exclusion of ischemic heart disease in an outpatient setting. Clin Res Cardiol 2006;95:461-7. (Pubitemid 44315785)
16. Khoo JP, Grundy BJ, Steadman CD, Sonnex EP, Coulden RA, McCann GP. Stress cardiovascular magnetic resonance in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings. Br J Radiol 2012;85:e851-7.
17. Karamitsos TD, Arnold JR, Pegg TJ, Cheng AS, van Gaal WJ, Francis JM et al. Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease. J Cardiovasc Imaging 2009; 25:277-83.
18. Karamitsos TD, Ntusi NA, Francis JM, Holloway CJ, Myerson SG, Neubauer S. Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:66.
19. Reyes E, Staehr P, Olmsted A, Zeng D, Blackburn B, Cerqueira MD et al. Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. J Nucl Cardiol 2011;18: 620-7.
20. Adenoscan [Package Insert]. Northbrook, IL: Astellas Pharma US, Inc. 21. Adenosine 30 mg/10 mL Solution for Infusion [Package Insert]. LL13 9UF, UK: Wockhardt UK Ltd.
21. Lexiscan [Package Insert]. Northbrook, IL: Astellas Pharma US, Inc. 23. Rapiscan [Package Insert]. London, UK: Pharma Solutions EU Ltd.
22. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, MilikienD et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28.
23. Beleslin BD, Ostojic M, Djordjevic-Dikic A, Nedeljkovic M, Stankovic G, Stojkovic S et al. Coronary vasodilation without myocardial erection. Simultaneous haemodynamic, echocardiographic and arteriographic findings during adenosine and dipyridamole infusion. Eur Heart J 1997;18:1166-74. (Pubitemid 27271890)
24. Alberti C, Monopoli A, Casati C, Forlani A, Sala C, Nador B et al. Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol 1997;30: 320-4. (Pubitemid 28006846)
25. Dhalla AK,Wong MY,Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2Aadenosine receptor agonists is mediated by direct sympathoexcitation inawake rats. J Pharmacol Exp Ther 2006;316:695-702. (Pubitemid 43130996)
26. Abidov A, Hachamovitch R, HayesSW, Ng CK, Cohen I, Friedman JD et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation 2003;107: 2894-9. (Pubitemid 36736629)
27. Hage FG, Iskandrian AE. Heart rate response during vasodilator stress myocardial perfusion imaging: mechanisms and implications. J Nucl Cardiol 2010;17:536-9.
28. Hage FG, Dean P, Iqbal F,HeoJ, Iskandrian AE.Ablunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2011;18:1086-94.
29. Iqbal FM, Al JaroudiW, Sanam K, Sweeney A, Heo J, Iskandrian AE et al. Reclassification of cardiovascular risk in patients with normal myocardial perfusion imaging using heart rate response to vasodilator stress. Am J Cardiol 2013;111:190-5.
30. Hage FG, Perry G,HeoJ, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.AmJ Cardiol 2010;105:839-43.
31. Gerber BL, Raman SV, Nayak K, Epstein FH, Ferreira P, Axel L et al. Myocardial firstpass perfusion cardiovascular magnetic resonance: history, theory, and current state of the art. J Cardiovasc Magn Reson 2008;10:18.
32. Cheng AS, Pegg TJ, KaramitsosTD, Searle N, Jerosch-Herold M, Choudhury RP et al. Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol 2007;49: 2440-9. (Pubitemid 46962268)
33. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012; 379:453-60.
34. Hamon M, Fau G, Nee G, Ehtisham J, Morello R. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson 2010;12:29.
35. Miller CD, HwangW, Case D, Hoekstra JW, Lefebvre C, Blumstein H et al. Stress CMR imaging observation unit in the emergency department reduces 1-year medical care costs in patients with acute chest pain: a randomized study for comparison with inpatient care. JACC Cardiovasc Imaging 2011;4:862-70.
36. Bhave NM, Freed BH, Yodwut C, Kolanczyk D, Dill K, Lang RM et al. Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson. J Cardiovasc Magn Reson 2012;14:89.